Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 8/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23210301 | 1.00 | CHRM4 (0.47) | CHRM4CHRM1CHRM2CHRM5HPGD | |
| SCHEMBL23209984 | 0.87 | CHRM4 (0.47) | CHRM4CHRM1CHRM2CHRM5SLC2A1 | |
| SCHEMBL23209986 | 0.87 | CHRM4 (0.47) | CHRM4CHRM1CHRM2CHRM5SLC2A1 | |
| SCHEMBL29843914 | 0.86 | CHRM4 (0.45) | CHRM4CHRM1CHRM2CHRM5 | |
| SCHEMBL23210043 | 0.86 | CHRM4 (0.45) | CHRM4CHRM1CHRM2CHRM5 | |
| SCHEMBL23210039 | 0.86 | CHRM4 (0.45) | CHRM4CHRM1CHRM2CHRM5 | |
| SCHEMBL23209883 | 0.83 | CHRM4 (0.46) | CHRM4CHRM1CHRM2CHRM5 | |
| SCHEMBL23212934 | 0.82 | CHRM4 (0.48) | CHRM4CHRM1CHRM2CHRM5SLC2A1 | |
| SCHEMBL23209831 | 0.81 | CHRM4 (0.61) | CHRM4CHRM1CHRM2CHRM5KMT2A | |
| SCHEMBL23209832 | 0.81 | CHRM4 (0.61) | CHRM4CHRM1CHRM2CHRM5KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12122761-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | NOVARTIS AG (CH) | 2024-10-22 | — | — | US | disclosed |
| CN-114555592-B | 2-Azaspiro [3.4] octane derivatives as M4 agonists | 诺华股份有限公司 | 2024-09-06 | — | — | CN | disclosed |
| US-20230212139-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-07-06 | — | — | US | disclosed |
| US-11548865-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | NOVARTIS AG (CH) | 2023-01-10 | — | — | US | disclosed |
| EP-4041389-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | Novartis AG (CH) | 2022-08-17 | — | — | EP | disclosed |
| CN-114555592-A | 2-azaspiro [3.4] octane derivatives as M4 agonists | 诺华股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20210107889-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-04-15 | — | — | US | disclosed |
| WO-2021070090-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS AG (CH) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107889-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | CHRM4 4/4885CHRM1 2/4885CHRM2 1/4885 |
| US-20230212139-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | CHRM4 4/4885CHRM1 2/4885CHRM2 1/4885 |
| US-12122761-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | CHRM2, CHRM1, CHRM3 | CHRM4 4/4885CHRM1 2/4885CHRM2 1/4885 |
| US-11548865-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | CHRM2, CHRM1, CHRM3 | CHRM4 4/4885CHRM1 2/4885CHRM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.